Promising blood cancer combo trial pulled before it even started
NCT ID NCT06284460
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial aimed to test a combination of two drugs—ASTX727 (already approved for some blood cancers) and ASTX029 (an experimental ERK inhibitor)—in adults with myelodysplastic syndromes (MDS) or related blood cancers that have a mutation in the RAS pathway. The goal was to find a safe dose and see if the combo could control the disease. However, the study was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASTX727 (decitabine and cedazuridine) and ASTX029 (an ERK inhibitor)
What this could lead to
If this trial had succeeded, it could have pointed toward a new treatment option for people with certain genetic mutations in MDS or MDS/MPN.
What could go wrong
This trial was withdrawn before any participants enrolled, so no results are available. The combination had not been tested in humans, and early-stage cancer trials often fail due to safety or lack of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Cente
Houston, Texas, 77030, United States